XELIRI or FOLFIRI as salvage therapy in advanced pancreatic cancer

Stefano Cereda, Michele Reni, Alessia Rognone, Michele Ghidini, Carmen Belli, Simona Longoni, Clara Fugazza, Matteo Brioschi, Roberto Nicoletti, Gianpaolo Balzano, Paolo Passoni, Eugenio Villa

Research output: Contribution to journalArticle

Abstract

Background: More than half of patients with pancreatic adenocarcinoma (PA) are candidates for further treatment when they experience upfront treatment failure. Patients and Methods: Patients with gemcitabine-resistant PA, age 50 were treated with a XELIRI or FOLFIRI regimen until progressive disease or a maximum of six months. As this was an observational study, no statistical design was performed. Results: Between July 2007 and December 2009, 34 patients (median age 60 years; median KPS 90) were treated with XELIRI (26) or FOLFIRI (8) regimen. Grade >2 toxicity consisted of neutropenia in 9% of patients, anemia and fatigue in 3% and hand-foot syndrome in 12%. Median progression-free survival was two months (range 1-4). Maximum response was stable disease in four patients (12%). Median survival was 4.2 (range 1-15) months. Conclusion: Fluoropyrimidine and irinotecan combination does not seem to have any role in the treatment of gemcitabine-resistant PA.

Original languageEnglish
Pages (from-to)4785-4790
Number of pages6
JournalAnticancer Research
Volume30
Issue number11
Publication statusPublished - Nov 2010

Keywords

  • FOLFIRI
  • Gemcitabine-resistant disease
  • Irinotecan
  • Pancreatic cancer
  • XELIRI

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'XELIRI or FOLFIRI as salvage therapy in advanced pancreatic cancer'. Together they form a unique fingerprint.

  • Cite this

    Cereda, S., Reni, M., Rognone, A., Ghidini, M., Belli, C., Longoni, S., Fugazza, C., Brioschi, M., Nicoletti, R., Balzano, G., Passoni, P., & Villa, E. (2010). XELIRI or FOLFIRI as salvage therapy in advanced pancreatic cancer. Anticancer Research, 30(11), 4785-4790.